With multiple brand new spec lab/ office suites and numerous shared amenities, 704 Quince Orchard promises to be the ‘best in class’ lab building in the I-270 Corridor.
The Maryland Industrial Partnerships program and the Maryland Technology Development Corp. will jointly host a free briefing about how faculty and local businesses can participate in funding programs at Frostburg State University on Sept. 11 at 2 p.m. in the Harold J. Cordts Physical Education Center Hall of Fame Room.
In the past several years, Greater Boston has cemented itself as the global epicenter of life sciences research. According to JLL’s Life Sciences Outlook report, the region consistently ranks in the top tier of U.S. life sciences clusters, with only San Francisco as its main adversary.
AstraZeneca PLC spinout Viela Bio Inc. filed for an IPO of up to $150 million.
Cambridge, U.K.-based AstraZeneca said in February 2018 that its research and development unit, MedImmune LLC, would move out six experimental compounds from its early-stage inflammation and autoimmunity programs to form Viela Bio, an independent biotech company.
The company hasn’t yet disclosed its share price or date for an initial public offering.
This group of young professionals was chosen from a pool of nearly 500 nominations.
Good job Arti Santhanam, John Gustin and Silvia Goncalves!
Calling all entrepreneurs and Innovators in the DMV area… Have you heard? JLABS @ Washington DC is coming to the District! In anticipation of our upcoming launch we are hosting a community mixer. This is a wonderful opportunity for those looking to expand your network, connect with other entrepreneurs, VCs, academics and industry leaders. You’ll get an chance to meet the local JLABS Team, learn about future programming and how to become a resident.
Here are seven pieces of wisdom and advice about the role of innovation in healthcare that executives from hospitals and health systems across the country shared with Becker’s Hospital Review in August:
Viela Bio today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for inebilizumab, an investigational anti-CD19 monoclonal antibody, for the treatment of patients with neuromyelitis optica spectrum disorder (NMOSD) — a rare autoimmune disease characterized by unpredictable attacks that often lead to severe, irreparable disability including blindness and paralysis.